Skip to main content

Table 3 Arm B (vaccine + GM-CSF): patient profiles, clinical data, and immunological outcomes

From: The immunological and clinical effects of mutated ras peptide vaccine in combination with IL-2, GM-CSF, or both in patients with solid tumors

Pt

Age

Cancer

Stage on enrollment

# of cycles

Off-study reason

PFS#(ms)

OS* (ms)

Immune response

Proliferative assay

Elispot

        

Pre-vaccine

Post-vaccine

Pre-vaccine

Post-vaccine

1B

55

Biliary

NED

3

PD

2.9

8.7

+

+

+

+

2B

33

Colon

IV

3

PD

2.9

16.9

-

+

NA

3B

51

Colon

IV

5

PPS/Lost to follow-up

9.2+

52.6

+

+

-

+

4B

48

Pancreatic

NED

13

Completed

35.4+

35.4

-

+

-

-

5B

51

Colon

IV

1

PD

1

1.5

ND

6B

38

Colon

IV

1

Refused further Tx

0.2+

8.3

ND

7B

60

Pancreatic

IV

3

PD

4.6

21

-

-

NA

8B

57

Colon

IV

3

PD

3.1

6.8

NA

9B

52

Colon

IV

3

PD

3.3

28.3

-

+

+

+

10B

58

Pancreatic

IV

3

PD

2.9

20.9

+

+

-

+

11B

45

Pancreatic

IV

2

PD

1

7.3

ND

12B

79

Colon

IV

3

PPS

12.9

42.1

-

+

-

+

13B

43

Colon

IV

3

PD

2.6

6.3

-

-

-

+

14B

78

Colon

NED

8

Left voluntarily

16.8

69

-

+

-

+

15B

63

Colon

IV

3

PD

2.8

11.6

+

+

-

+

16B

64

Colon

IV

6

PD

5.7

20.7

-

+

-

-

17B

71

Colon

IV

6

PD

5.6

25.9

-

+

-

+

18B

58

Pancreatic

IV

2

PD

2.6

3.3

ND

  1. #Progression free survival was calculated as time from the date the consent was signed until evidence of disease progression or last follow-up without progression (+). *Overall Survival was calculated as time from consent date until death or last follow-up (+). ND, not done because patient received 2 or less vaccines; NA, sample not available. Arm B (Vaccine + GM-CSF): Patient Profiles, Clinical Data, and Immunological Outcomes.
  2. Abbreviations: NED No Evidence of Disease, PD Progression of Disease, PPS Poor Performance Status, SD Stable Disease, PFS Progression Free Survival, OS Overall Survival, ms Months.